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Background: In 2006 there were 432,700 people in Australia who had acquired brain injury (ABI) with some
limitation of activities; 90% of these were traumatic brain injuries (TBIs) and nearly a third sustained injury below
age 15 years. One to four years post injury, 20% to 46% of children with traumatic brain injury (TBI) have clinically
significant disorders of attention. There is controversy as to whether central nervous system (CNS) stimulants can be
an effective method of treating these.
Objectives were to determine the efficacy of CNS stimulants for children with TBI, and to calculate the sample size
for a larger trial using the Conners’ 3 Parent Rating Scales Score as the primary endpoint.
Methods: Pilot series of aggregated prospective randomised, double-blind, n-of-1 trials of stimulant versus placebo
within individual patients. Setting: tertiary children’s public hospital. Participants: ten children aged 6 to 16 years
more than 12 months post TBI with attention, concentration and behavioral difficulties on stimulants. Interventions:
Three cycles of methylphenidate or dexamphetamine orally at doses titrated by physician compared to placebo.
Main Outcome Measures: Conners 3 Parent (Conners 3-P) and Teacher (Conners 3-T) Rating Scales (Global Index),
Behaviour Rating Inventory of Executive Function (BRIEF) and Eyberg Child Behaviour Inventory (ECBI).
Results: Five of ten patients completed the study. Data from 18 completed cycles from seven patients were
analysed. The posterior mean difference between stimulant and placebo scores for the Conners 3-PS (Global Index)
was 2.3 (SD 6.2; 95% credible region −1.0 to 6.1; posterior probability that this mean difference was greater than
zero was 0.92), and for the Conners 3-T (Global Index) the posterior mean difference was 5.9 (SD 4.5; 95% credible
region −3.1 to 14.9; posterior probability 0.93). Posterior mean differences suggest improvement in behaviour and
executive function and a decrease in number and intensity of child behaviour problems when taking stimulants
compared to placebo. Taken together these data are suggestive of a small benefit at group level.
Conclusions: In this pilot study, there was sufficient evidence that stimulants may be useful in management of
behavioral and cognitive sequelae following TBI, to warrant a larger trial.
Trial registration: The trial was registered with the Australian and New Zealand Clinical Trials Registry: registration
number ACTRN12609000873224.
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In 2006 there were 432,700 people in Australia who had
acquired brain injury (ABI) with some limitation of ac-
tivities; 90% of these were traumatic brain injuries (TBIs)
and nearly a third sustained injury below age 15 years
[1]. One of the most common sequelae of brain injury is
difficulties with attention, concentration and self-
regulation [2,3]. One to four years post injury, 20% to
46% of children with TBI have clinically significant disor-
ders of attention [4,5]. This has been compared to devel-
opmental forms of Attention Deficit Hyperactivity
Disorder (ADHD). The term ‘secondary ADHD’ was in-
troduced by Gerring et al. [6] to describe significant dif-
ficulties with concentration, impulse control and
hyperactivity that occur following brain injury, rather
than from developmental causes. It has been noted that
in those with ABI the pathophysiology is likely to be
very different to primary ADHD, and that hyperactivity
may be generally less severe [6], with the inattentive sub-
type predominating in at least the first two years post in-
jury [7,8]. Another study found that children with TBI
and ADHD had worse performance compared with the
TBI-only group, on measures of attention, executive
functioning, and memory. In children with severe TBI,
the behavioral diagnosis of ADHD was associated with
more difficulty in attention, executive functioning, and
memory. Additionally, greater deficits in memory skills
were found in the secondary ADHD group compared
with children with premorbid ADHD that persisted after
injury [9].
Despite a good body of evidence delineating the seque-
lae of TBI, there are few validated interventions to re-
mediate cognitive deficits in children following TBI [9].
While central nervous system (CNS) stimulant medica-
tion is generally a well-accepted treatment for develop-
mental ADHD, there is controversy as to whether
stimulant medication can be an effective method of
treating acquired attention deficits. While some studies
have reported a positive effect of stimulant medication
on attention, concentration and impulsivity post injury
(Bakker and Waugh, unpublished data; [10,11]) and par-
ticularly in those with pre-injury ADHD [12], others
have reported a null result [13]. However, there are a
limited number of studies on the efficacy of CNS stimu-
lants on children following TBI, with a range of methodo-
logical issues that may impact on outcomes, including
designs varying from case studies to randomised con-
trolled trials (RCTs), limited sample sizes, and variable
times since injury, ages at injury, type and doses of stimu-
lant medication, type of data collected (retrospective
versus prospective), and qualitative versus quantitative
outcome measurement. Two main early studies found
contradictory results regarding the efficacy of methylphen-
idate in treating children with acquired attentionaldisorders secondary to brain injury. The first was a
double-blind, placebo-controlled, cross-over trial in 14
children with varying degrees of head injury. Differences
between drug and placebo groups uniformly achieved stat-
istical significance [14]. The second was a double-blind,
placebo-controlled, cross-over trial conducted in ten
paediatric subjects with TBI ranging from mild to severe.
No significant differences between methylphenidate and
placebo were found on measures assessing behavior, atten-
tion, memory, and processing speed [13]. A 2004 system-
atic review of stimulant effectiveness in treating attention-
deficit/hyperactivity disorder secondary to traumatic brain
injury (ADHD/TBI) found that methylphenidate (MPH)
effects on behavior (hyperactivity, impulsivity) were evi-
dent but were not as robust as those typically observed
with MPH in primary ADHD. The effect of MPH on cog-
nition was less apparent. More favorable outcome was as-
sociated with initiation of treatment soon after head injury
(although this factor was not systematically studied), and
trials with relatively long durations [15]. They concluded
that there is need for rigorous treatment outcome re-
search among representative samples of ADHD/TBI indi-
viduals. A recent systematic review [10] assessed sixteen
studies examining the effectiveness of stimulants following
paediatric ABI, and concluded that teams treating paediat-
ric ABI need to assess for the presence of inattention and
consider the use of stimulants with individualised n-of-1
monitored trials, as stimulants have been used in children
with impaired attention and hyperactivity following ac-
quired brain injury (ABI) with positive results.
Bakker and Waugh completed a double-blind placebo-
controlled randomised trial of stimulant medication in
21 children with TBI [16,17] at The Children’s Hospital
at Westmead. Of 21 children, 43% of the sample had
a positive response to either dexamphetamine (DEX)
or methylphenidate (MPH), with 6/10 responding posi-
tively to DEX. Most studies describe the use of MPH;
[8-14,18,19]. However, other CNS stimulants, such as
DEX, may be effective as children may have a differential
response [12]. Given contradictory literature findings,
and indications of the potential efficacy for individuals,
the need for objective measurement on a case by case
basis is clear.
n-of-1 trials
n-of-1 trials are multiple-cycle, double-blind, placebo-
controlled cross-over trials using standardised measures
of effect, with randomisation order independently gener-
ated for each patient. They provide the strongest evi-
dence possible about treatment efficacy in an individual
patient [20]. This may be particularly important in the
ABI population, as there may be positive effects for
some individuals (‘responders’) as opposed to others
(‘non-responders’); [11,13,16].
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erally smaller than for adult RCTs, making it difficult to
achieve a sample with adequate power when undertaking
conventional parallel arm RCTs. Aggregated n-of-1 trials
are ideally suited to paediatric populations, as the sample
size required to achieve adequate power is considerably
less [21]. Additionally, individual responses are available
for feedback to participants and their carers [21]. As no
previous n-of-1 trials have been conducted in this area, this
reported series of n-of-1 trials significantly enhances paedi-
atric community rehabilitation knowledge and practice.
Objectives were 1) to determine the efficacy of central
nervous system stimulants for children with traumatic
brain injury and 2) to determine the effect size using
the Conners’ 3 Parent Rating Scales Score as the primary
endpoint in this pilot study. This would later be used
to calculate the sample size for a larger trial. The
main hypothesis was that stimulant therapy compared
to placebo would significantly improve attention and
concentration, and executive dysfunction including




The full protocol can be accessed at [http://www.ncbi.
nlm.nih.gov/pmc/articles/PMC3668233/].
A summary of the protocol follows.
Each child completed three pairs of one-week treatment
periods (placebo versus stimulant medication), making a
total of six weeks. To account for ‘wash out’, no measure of
efficacy was taken on the first two days of each seven-day
period. The order of drugs in each cycle was determined by
computer-generated random allocation, blinded to clin-
ician, parent, teacher and patient. A computer generated
randomisation schedule (random number sequence) cre-
ated by the study statistician and held by the site pharma-
cies (and not accessible to investigators) predetermined
the order of medication (stimulant (MPH or DEX) or pla-
cebo) in each cycle. A Research Assistant enroled partici-
pants, and the hospital clinical trials pharmacist sequentially
assigned participants to random allocation sequences.
Within each pair, the sequence was randomly allocated. For
example, an actual sequence was (drug, placebo), (drug, pla-
cebo), (placebo, drug). At the end of the trial, the order of
medications was unmasked, and compared with the parent
and teachers’ observations of the child’s behaviour.
Outcome measures
The investigators selected the following outcome measures:
Primary
 Conners’ 3 Parent Rating ScalesSecondary
 Conners’ 3 Teacher Rating Scales
 Behaviour Rating Inventory of Executive Function
(BRIEF - Parent/Teacher/Self-Report)
 Eyberg Child Behaviour Inventory (ECBI)
Participants
Participants in the study were purposefully sampled
children who fitted the inclusion criteria and who were
known to the Queensland Paediatric Rehabilitation Service,
Brisbane. Australia (tertiary children’s public hospital).
Inclusion criteria
1. Between 6 and 16 years old.
2. Clinical diagnosis of moderate to severe traumatic
brain injury, with severity based on duration of loss
of consciousness, initial Glasgow Coma Scale
(GCS) Score at presentation to the treating
hospital, and duration of post-traumatic amnesia
(PTA). Moderate TBI was defined as loss of
consciousness for 30 to 60 minutes, or GCS 9
to 12, or PTA from one day to one week; and
severe TBI was defined as loss of consciousness
for greater than 60 minutes, or PTA greater than
one week, or GCS less than 9.
3. At least 12 months post injury.
4. Clinically significant attention/concentration
disorder or executive dysfunction including
disorders of behavioural or emotional regulation that
may respond to stimulants.
5. At least two people (parent or other person and
teacher) available to monitor the child’s symptoms.
Exclusion criteria
1. Uncontrolled seizure disorder, moderate to severe
hypertension, clinically significant anxiety, motor
tics, Tourette syndrome, suspected or proven
cardiac conduction problems, idiosyncratic reaction
to sympathomimetic amines, history of drug abuse
(including high caffeine beverages and appetite
suppressants).
2. Parents not able to fill out forms in English.
3. Child’s school unwilling to participate.
Measures
A. Baseline: age, gender, type and duration of
symptoms, reason for referral, time post injury,
presence or absence of ADHD (DSM-IV criteria)
[22], demographics, and details of previous
stimulant therapy.
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capable children over 12 completed a weekly diary,
including the following measures:
1. Conners’ 3 Rating Scales for Parent and Teacher
[23]. These are well-known valid and reliable
scales [24] for measuring ADHD symptoms, in
children aged 3 to 18 years of age. Subscales
include inattention, hyperactivity/impulsivity,
learning, executive functioning, aggression and
peer relations, as well as subscales mapping onto
DSM-IV criteria for ADHD (inattentive), ADHD
(hyperactive-impulsive), ADHD combined,
Conduct Disorder, and Oppositional-Defiant
Disorder. Means and standard deviations for
the global index vary dependent on age (for
6 year-olds the mean is 5.15 with a standard deviation
of 3.97; means for 17 to 18 year-olds are 3.90
with a standard deviation of 4.00). The Global
Index subscale was used for monitoring change
in severity of behavioural symptoms over time.
For teachers, the possible score ranges from 0 to
30. Raw scores are usually converted to T-scores or
percentile scores relative to normative data. T-scores
above 60 (percentiles above 84) are considered
clinically significant.
2. Behaviour Rating Inventory of Executive Function
(BRIEF - Parent/Teacher/Self-Report); [25]. This
assesses executive function behaviors of school-age
children in the home and school environments
(parent and teacher versions). The Global Executive
Composite was analysed. The Global Executive
Composite (GEC) is an overarching summary score
that incorporates all of the BRIEF clinical scales.
The possible range of scores for teachers is 0 to 24.
It has satisfactory reliability and validity [25].
3. Eyberg Child Behaviour Inventory (ECBI) [26].
This parent-rated scale measures two outcomes:
Total Intensity scores and Total Problems scores.
The intensity score is the total frequency of
occurrence for the 36 behaviours and the problem
score is the total number of behaviours for which
the response is ‘yes’. Both scales of the ECBI are
continuous such that higher scores on the scale
indicate a greater level of conduct-disordered
behaviour and greater impact on the parent.
There are two clinical cut-off scores: 127 on
intensity (maximum = 252) and 11 on problem
(maximum score = 36). Reliability and validity of
this measure have been well-established [27,28].
C. Post trial: post trial medication management plan.
Medication
Prior to the study, if not already stabilised on stimulant
medication, the child was stabilised on an individualisedoral dose of MPH or DEX. This was done to account
for the wide variation in clinical dose required by chil-
dren using stimulants and to identify significant side ef-
fects. If the child was not already stabilised on
methylphenidate or dexamphetamine, prior to the trial
commencement they were stabilised on an appropriate
individualised dose. They were stable on this dose for
approximately two weeks prior to commencement of the
trial, unless already on stimulant medication prior to re-
cruitment. The appropriate dose was one that provided
a clinical improvement in target behaviours, and was
well-tolerated with minimal side-effects, up to the max-
imal recommended dose stated by the product informa-
tion. If unacceptable side effects occurred while taking
one of the stimulants, the trial was offered using the
other medication.
Children already on long-acting MPH and those
judged likely to benefit from this were offered long-
acting MPH trials at their clinician’s discretion. Other
children were offered trials of short-acting MPH, or
DEX, twice daily.
Stimulant and placebo were provided as identical
opaque capsules, using encapsulation of either MPH or
DEX powder, or over-encapsulation of the active whole
tablet for long-acting MPH where the pharmacodynam-
ics would not be altered by this. The pharmacy pro-
duced 3 × 1 week’s supply of each, packaged into
Webster packs as per the computer generated random-
isation order.
Procedure
The University of Queensland Medical Research Ethics
Committee and the Royal Children’s Hospital and Health
Service District Human Research Ethics Committee,
Queensland Health gave approval for this research
study. Approval was obtained from Education Regula-
tory Authorities in Queensland (Queensland Govern-
ment Department of Education and Training, and
Catholic Education Archdiocese of Brisbane). Fully in-
formed consent from parent and teacher (and assent
for children over 12) was obtained.
Hospital clinicians determined subject eligibility, ti-
trated stimulant medications and completed pre-trial
(baseline) assessments. Parent/guardians provided con-
sent forms, information sheets and questionnaires to
schools for a teacher to complete weekly measures. Chil-
dren then completed three pairs of one week treatment
periods (placebo versus stimulant medication). All data
were returned to research staff who provided a report to
the treating doctor to discuss with the family.
Statistical analysis
Three types of Bayesian results will be presented here:





Of these, 3 patients withdrew (b)
7 completed 1 cycle
Of these, 1 patient withdrew end of  
week 3 (c)
6 completed two cycles
Of these, 1 patient withdrew at the end 
of week 4 (d) 
5 patients completed study 
Of 15 eligible patients  (a)
Figure 1 Patient flow chart. (a) Five eligible patients did not enrol
because teacher consent was not obtained. (b) Two patients
withdrew before commencing; they were under guardianship of the
Department of Community Services, which withdrew consent. A
third patient changed stimulant after consenting to the trial and
therefore did not take trial medication. (c) One patient decided to
withdraw at end of week 3 as they were confident which period
was active and decided they would prefer to be on medication for
exams. (d) A fifth participant withdrew toward the end of the study
(after week 4), however the reason is uncertain.
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gives the best estimate of the overall effect size differ-
ence between treatments; (ii) the associated 95% credible
region, which give intervals of uncertainty (in this case
the 2.5 and 97.5 percentile) of the posterior distributions
used in (i); and (iii) the posterior probability of the mean
difference that stimulant scores were better than placebo
scores, which describes the likelihood that the patients
will favour the active treatment in future cycles. While
seemingly analogous to confidence intervals in frequen-
tist statistics [29], Bayesian credible regions have quite
different interpretations and do not always coincide
with confidence intervals as they incorporate problem-
specific contextual information from the prior distribu-
tion and treat nuisance parameters radically differently
[29]. However, like confidence intervals, a credible re-
gion that does not include the null value provides stron-
ger evidence for the estimate in question than a credible
region that includes the null value. Raw scores for the
18 cycles from the seven patients who completed at least
one cycle were included in the statistical analyses.
Means, standard deviations (SDs) and ranges were cal-
culated for stimulant and placebo periods. Replicating
the technique described by Zucker et al. [29], hierarch-
ical Bayesian random effects models were used to com-
bine the n-of-1 studies to obtain estimates of treatment
effectiveness for the group. Non-informative prior distri-
butions were employed and inverse χ2 distributions (with
the number of degrees of freedom given by the har-
monic mean of the individual sample sizes) were used to
give increased weight to within-patient heterogeneity es-
timates from patients with larger number of available
measurements. Estimates of mean treatment difference,
95% credible regions (95% CRs), and posterior probabil-
ities were determined. An important difference between
treatment means was defined to occur if the 95% CR did
not include the null value. Numerical results from the
hierarchical Bayesian models were derived from com-
puter simulation in WinBUGS [30]. Simulations of size
N = 50,000 were run in five parallel chains after a burn-
in period of 5,000 iterations. Convergence in the final
samples was checked using visual plots of simulation
histories and the modified Gelman-Rubin statistic [31].
The trial was to be stopped if the Data Safety Monitor-
ing Board recommended stoppage due to safety concerns.
Results
Ten patients commenced n-of-1 studies over the 2009
school year, and five completed all three treatment cy-
cles; see Figure 1. Data were available for eighteen com-
pleted treatment cycles from seven patients. The
demographic and injury characteristics of the partici-
pants are presented in Table 1. GCS at the time of injury
ranged from 3 to 15 (those with GCS ≤ 12 were thought
Table 1 Demographic and injury characteristics of participants






Cause of TBI History of ADHD Medication PTA (or why not)
(years) Y = yes
1 M 14 < 8 Severe 5 years 9 Y Paed versus MVAb Reported ‘no’ DEX 5 mg bd Not done (age)
2 F 10 ? Severe 18 months 8 Y NAIa Too young Unknown Not done (age)
3 M 13 3 Severe 9 years 4 Y MVA Concentration and
learning difficulties;
but no diagnosis
DEX 10 mg mane
and lunch
Not available
4 F 11 6 Severe 6 years 5 Y Paed versus MVAb Unknown MPH 10 mg mane
5 mg lunch
34 days
5 M 16 10 Severe 12 years 4 Y Fall (6 m) Concentration and
learning difficulties;
but no diagnosis
MPH 30 mg mane 4 weeks
6 M 16 15 Moderate to severe 14 years 2 N Bicycle (fall) Reported ‘no’ MPH LA 1 to 2 days
7 M Approximately 13 < 8 Severe 9 years Approx 5 N Bicycle versus MVA Pre-injury ADHD
diagnosis and treatment
(methylphenidate)
MPH Not done (nonverbal)




9 F 13 5 Severe 6 years 7 N NAIa No developmental
concerns prior to injury






10 F 8 11 Moderate 26 months 6 N NAIa Too young Concerta 36 mg Not done (age)
Comp, completed trial; DEX, dexamphetamine; GCS, Glasgow Coma Scale; MPH, methylphenidate; MVA, motor vehicle accident; aNon-accidental injury; bPedestrian hit by motor vehicle; PTA, post-traumatic amnesia.
Note 3 and 5 had reported exacerbation of concentration and learning difficulties post TBI.
Imaging
1. Computer tomography (CT) head (time of injury): fracture of the left ethmoid region as well as parenchymal haemorrhages in the right occipital region.
2. CT head (time of injury): injuries included bilateral subdural haematomas and bilateral retinal haemorrhages. There were no fractures associated with the injury.
3. CT (initial; reported): he had a right extradural haematoma and significant cerebral contusions including his frontal lobe.
4. CT scan (initial) showed a diastasis of the right occipito-temporal suture in addition to a minimally displaced base of skull fracture, no intracranial lesions and a probable fracture through the left TMJ articular fossa.
5. Comminuted and depressed skull fracture of the right parietal and frontal bones (transversing the skull at the base of the sphenoid), with multiple areas of contusion and haemorrhage in the right frontal and
temporal lobes with midline shift and overall swelling of the right cerebral hemisphere with midline shift.
6. Left temporal fracture with left extradural haematoma and haemorrhagic contusions involving the frontal and temporal lobes.
7. Diffuse axonal injury, multiple contusions, cerebral oedema, uncal and tonsillar herniation and haemorrhages involving the left basal ganglia and left cerebellum.
8. Not done.
9. Large left subdural haematoma with associated cerebral oedema.
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ation of post-traumatic amnesia). Seven patients trialled
MPH (two of these slow release), one DEX, and for two
this information is unknown. Of the five who did not
complete the trial, three withdrew before commencing. Of
these, two were under guardianship of the Department of
Community Services, which withdrew consent. One chan-
ged stimulant after consenting to the trial and therefore
did not take trial medication. One participant withdrew at
end of week 3 as they were confident which period was
active and decided they would prefer to be on this medica-
tion for their school examinations. One withdrew toward
the end of the study, with no reason given. Figure 1 shows
the participant flow diagram of the study. The pilot ended
after the target of ten patients was reached.
There was considerable individual variation in results.
Since the aim of the full study is to determine the group
effect of stimulants on attention, hyperactivity and ex-
ecutive function in children with TBI, this report will de-
scribe aggregated findings, as described by Zucker and
colleagues [29]. These are shown in Figure 2 and Table 2.
Heterogeneity was not assessed between participants,
due to the small participant numbers.
Conners’ 3 Rating Scale
The posterior probabilities that the mean difference be-
tween stimulant scores and placebo scores was greater
than zero were 0.92 for parents and 0.93 for teachers for
the Global Index, indicating a trend towards active
medication improving behaviour compared to placebo.
For the Global Index, there was a small difference be-
tween all placebo and all stimulant treatments, more
marked for teachers’ scores (posterior mean difference
5.9 (SD 4.5), 95% credible region −3.1 to 14.9, possible
score 0 to 30) than parents’ scores (posterior mean dif-
ference 2.3 (SD 6.2), 95% credible region −1.0 to 6.1).
Raw scores rather than adjusted scores were used for
reasons explained in the discussion.
Executive function
Teacher-reported executive function (measured by the
BRIEF) showed an improvement on active medication
compared to placebo across all cycles (posterior mean
difference 20.7 (SD 23.2); possible range 0 to 24; 95%
credible region −25.2 to 67.2). Correspondingly, the pos-
terior probability of the overall mean difference that
stimulant scores were better than placebo scores was
0.86 for teachers, somewhat higher than 0.76 for parents,
where the posterior mean difference was 10.8 (SD 17.5
(95% credible region −23.5 to 46.7).
Eyberg Child Behaviour Inventory
Parent-reported number of child behaviour problems
and teacher rated intensity of child behaviour problemsshowed improvement on stimulant treatment compared
with placebo treatment; posterior mean difference 2.8
(SD 4.8; 95% credible region −6.8 to 12.3) and 24.8 (SD
32.7; 95% credible region −40.6 to 90) respectively, and
posterior probability of the overall mean difference that
stimulant scores are better than placebo scores WAS
0.75 and 0.83, respectively. There was very little differ-
ence between stimulants and placebo in the intensity
of child behaviour problems in parent reports; poste-
rior mean difference 2.9 (SD 13.7; 95% credible re-
gion −19.7 to 36.6), posterior probability of the overall
mean difference that stimulant scores are better than
placebo scores WAS 0.49.
Although all these posterior mean differences showed a
positive trend in favour of stimulants, all 95% credible re-




This pilot project assessed the effect of psychostimulants
on attention, hyperactivity and higher cerebral functions
of children with traumatic brain injuries. While stimu-
lants are approved for children with ADHD, the children
in this study had symptoms consistent with ADHD due
to trauma. A larger trial is required to assess the efficacy
of stimulants on this group of children.
There were several methodological issues. The first is
that we elected to treat children with TBI displaying
symptoms similar to ADHD, with stimulants. Those
without those symptoms were not considered: therefore
this pilot was conducted on a sub-population of children
with TBI. We recognize that this method does introduce
a selection bias by selecting those who appeared to de-
rive benefit. However, in any trial, it would be unethical
to offer participation where there is little likelihood of
benefit. The results of this pilot and the subsequent lar-
ger trial can only be generalised to those children who
have an apparent pre-trial clinical effect from stimulant
medication.
Secondly, previous experience with conducting a trial
of stimulants where there was a pre-trial titration with
fixed doses of stimulants to find the dose with the best
apparent effect, showed that large numbers of children
were randomized but withdrew, due to the length of the
pre-trial titration [21]. Further, several participants with-
drew because their parents were concerned that their
children would be receiving placebo.
It was considered that the best option was to find a
dose of stimulants in each individual that appeared to
produce positive behavioural results and was well toler-
ated, until a ceiling dose was reached. We believe this
approach is valid, in the same way that some RCTs have
an escalating scale of doses until either an effective dose
Conners index - parent
Conners index - teacher
BRIEF - parent
BRIEF - teacher
ECBI problem - parent
ECBI intensity - parent
ECBI intensity - teacher
-40 -20 0 20 40 60 80
Posterior mean difference [placebo-stimulant scores]
Favours stimulant Favours placebo
Figure 2 Overall posterior population estimates of the mean difference between stimulant and placebo score (square) together with
associated 95% credible region (line) for each study instrument. Placebo minus stimulant scores are shown. Lower scores indicate less
disturbance of behaviour. Scores above zero favour stimulants and below zero favour placebo. Crossing the line means a result is non-significant.
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achieved. The trial is thus comparing a clinically effect-
ive dose with placebo in each child.
Thirdly, there are no validated scales that measure
hyperactivity in brain injured children. The Conners’ 3
Rating Scales are designed for non-brain injured chil-
dren. Given that current regulations for the prescription
of stimulant medications in Australia require a diagnosis
of ADHD, this is the only feasible scale. HoweverTable 2 Number of completed cycles, global means (SD) and
posterior population estimates of the mean difference betwe




n (%) Mean (SD) (Rang
Conners 3 Rating Scale Global Index2,3
Parent 18 (90) 10.9 (4.9) (2 to 1
Teacher 10 (50) 6.5 (4.4) (0 to 1
Behaviour Rating Inventory of Executive Function2
Parent 18 (90) 147.8 (29.8) (88 to 2
Teacher 10 (50) 127.4 (24.1) (87 to 1
Eyberg Child Behaviour Inventory2
Parent: number of problems 17 (85) 8.5 (7.6) (0 to 2
Parent: intensity of problems 18 (90) 104.8 (26.5) (62 to 1
Teacher: intensity of problems 10 (50) 74.6 (20.8) (45 to 1
1Placebo minus stimulant scores; 2Lower scores indicate less disturbance of behavionormative scales have yet to be created for this popula-
tion. Most participants scored above the 97th percentile
on normative data for children without TBI for the be-
haviours tested for in both placebo and stimulant cycles,
that is, the very worst end of the scale for the perform-
ance of non-brain injured children. There is a reasonable
spread of raw scores that map to these high percentiles,
and a differential between raw scores is possible and
was in fact observed between stimulants and placebo.range of stimulant and placebo scores, and overall
en stimulant and placebo scores together with the
an the placebo scores for each study instrument
Placebo Posterior mean difference1 (PMD)
e) Mean (SD) (Range) Mean (SD) P(PMD > 0)
8) 13.3 (5.4) (4 to 21) 2.3 (6.2) 0.92
1) 11.0 (5.2) (2 to 21) 5.9 (4.5) 0.93
04) 152.3 (27.4) (106 to 195) 10.8 (17.5) 0.76
48) 143.2 (20.2) (100 to 181) 20.7 (23.2) 0.86
7) 10.3 (8.7) (0 to 25) 2.8 (4.8) 0.75
72) 109.1 (31.6) (47 to 164) 2.9 (13.7) 0.49
03) 93.0 (34.7) (57 to 176) 24.8 (32.7) 0.83
ur; 3Raw scores.
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between trial arms calculated in terms of changes in
these. This will be explored more thoroughly in the ana-
lysis of the full trial. The full trial, currently underway,
involves two other sites, and will recruit 42 children over
two years.
Finally, we conducted the trial with either MPH or
DEX, depending on patient and parent preference.
Clinically, the two medications are interchangeable.
Those children already on slow-release preparations of
MPH did the trial on this medication, as the half-life of
the MPH released is identical to immediate release
preparations.
An evidence-based review conducted by the McMas-
ter University Evidence-Based Practice Center Group
studied 23 articles on specific drug-to-drug compari-
sons [32]. These included eight studies comparing
MPH and DEX. Also included were studies comparing
different formulations of the same drug. Three studies
compared regular and sustained-release formulations of
MPH, and one study compared different isomers of
MPH (L-MPH versus D-MPH). Finally, one study com-
pared DEX and levoamphetamine. The stimulant-
stimulant comparisons documented few, if any, differ-
ences between MPH and DEX. The studies comparing
different formulations of the same drug revealed no sig-
nificant formulation effects.
With any crossover trial, the possibility of carryover ef-
fects needs to be considered. Swanson and Volkow [33]
investigated the pharmacological properties of MPH and
reported uptake and clearance times of oral short-acting
MPH from the brain using Positron Emission Tomog-
raphy studies. Uptake time orally is approximately 20 mi-
nutes and the clearance time is approximately 90 to
120 minutes. Regardless of dose, the time to maximum
concentration (Tmax) is reported as 1.5 to 2 hours and
t1/2 between 2 and 3 hours. The maximum behavioural
effects (reductions in overactivity, impulsivity and in-
attention) occur about 1 to 2 hours after oral doses, and
the effects dissipate significantly after 2 hours (3 to 4 hours
after each immediate release dose). Due to the small num-
ber of available data, we did not conduct any formal
‘carry-over’ checks/analyses - and instead were guided by
pharmacological and biological considerations. As such,
data taken on the first two days of each seven-day period
were omitted from the analyses to allow for washout. In-
formal graphical checks by day were drawn to visually as-
certain patterns or trends in the data beyond variability.
None were seen. If carry-over effects do exist, then the
treatment effect estimates might be underestimated, as
these effects would spill into the placebo results. The ran-
domisation of treatments within cycles would reduce this
effect, should it exist. In a larger confirmatory trial, forma-
lised checks would need to be conducted.There are some obvious limitations of this pilot study.
The sample size is small and the completion rate was
only 50%. Thus, individual scores are highly influential
and there is reduced power to find important overall
differences that may exist. Secondly, the distribution of
the mean differences was assumed to be normal. No
evidence existed to challenge this assumption and, in-
voking the central limit theorem, it is likely that this as-
sumption is not unreasonable. In the larger trial this
will be formally tested. Thirdly, those children who had
negative responses or adverse events during pre-trial ti-
tration are not included in the analysis. Finally, one
child withdrew because of correctly perceived success
of the treatment. Because he/she did not complete all
treatment cycles, there was relatively less data for this
‘success’ and thus more associated individual variability,
which may have biased results towards the ‘null’ differ-
ence between treatments.
Recruitment was impacted by a substantial percentage
of potentially eligible children (estimated to be 17% of
those screened) who were involved with the Department
of Child Safety, which did not give consent for those
children to participate. These were different to the five
eligible patients (described in Figure 2), who did not
enrol because teacher consent was not obtained. Re-
search staff endeavoured to work with department staff
to encourage participation by children involved with the
department. However, permission to participate was de-
nied in all cases even though this study was evaluating
the medication that the child was already taking, not
introducing any new treatments.
Though there were five withdrawals, not unusual in
this population [34], enough cycles (18) were completed
to allow Bayesian analysis of the aggregated completed
cycles.
The n-of-1 trial design has several strengths [35]. n-of-
1 studies provide the strongest evidence possible of the
effect of a medicine on an individual. A report is pro-
vided to patients and clinicians on the efficacy of the
treatment for the individual immediately after the trial is
concluded. This is not possible in a standard RCT. In
addition, every participant receives both the active and
placebo treatments, thus making participation more at-
tractive than in an RCT where there is a chance of being
randomised to the placebo arm of the trial. Finally, be-
cause the same person contributes multiple data points
to both the active and placebo arms of the trial, the sam-
ple is perfectly matched. The sample size required to
complete the trial is considerably smaller than a stand-
ard RCT, thus allowing credible data to be collected in
small populations where a standard RCT is virtually im-
possible to conduct.
Finally, if a participant leaves the trial early, completed
cycles can contribute to the final analysis. This is in
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the trial before completion are lost.
Validated ratings of concentration, executive functioning
and behaviour were used in this pilot study, and a strength
of this study is that ratings were obtained from both par-
ents and class teachers. Given that neuropsychological as-
sessments are time-consuming and therefore expensive,
validated ratings of concentration, executive functioning
and behavior are a practical method of measuring out-
comes, as well as directly obtaining data on a child’s func-
tioning as opposed to underlying impairments.
There was a greater difference between scores on
stimulant medication compared to placebo for teachers
compared to parents. A similar pattern was found by
Bakker and Waugh [16,17], although by contrast, in the
current study teachers were blinded. A possible explan-
ation for this trend may be that a child’s difficulties with
concentration and self-regulation are more evident in
the school setting where the child is expected to be able
to concentrate and regulate their behaviour for extended
periods of time, where difficulties may not be as evident
at home where formal learning is not expected and the
child’s difficulties with regulation and concentration may
not impact overly on their free play.
Hierarchical Bayesian analysis
Hierarchical Bayesian models have been advocated for
the analysis of n-of-1 trial data, especially when both
patient-specific and population estimates are desired
[30,36,37]. Detailed accounts of these models for normal
[30] and binary [37] outcome data have been previously
described. Advantages of this approach include the abil-
ity to embody prior information, coherently update this
prior information with the availability of new empirical
information, provide patient-specific and population
probabilistic results, allow covariate and participant sub-
group structures, accommodate the natural hierarchies
and clusters within patient groups, and easily handle un-
balanced data [36]. Exploiting these properties and the
sequential nature of n-of-1 trials, the population effect
size can be given by the posterior distributions of the ag-
gregated n-of-1 trials. The addition of new trials will up-
date and refine this posterior distribution; in a similar
manner to how evidence is accumulated between studies
with meta-analyses.
Conclusions
The results of this pilot and the subsequent larger trial
can only be generalized to those children who have an
apparent pre-trial clinical effect from stimulant medica-
tion. The major issues affecting generalisability here are
those who are eligible but [1] do not participate and [2]
those who withdraw before completing any cycles. If
these participants are importantly different from thosewho complete at least one cycle, then inherent biases
will result. However, missing data not at random will
have relatively little impact on those who complete at
least one cycle - because of the hierarchical structure of
the analysis, where individual effect sizes are estimates,
and their distribution falls under an overall mean distri-
bution. The impact is also minimised by the cross-over
benefit of patients being their own controls, over all
known and unknown confounders.
In this pilot study, there was sufficient evidence to
proceed to a formal series of aggregated n-of-1 trials.
Stimulants appeared to produce a small effect on behav-
iour and executive function for children with TBI on the
Global Index on the Conners’ 3 Rating Scales (both parent
and teacher) and for the Global Executive Composite on
the BRIEF. However, for the latter, the parent ratings var-
ied substantially and, with such small sample sizes, esti-
mates may have been unduly influenced by one or two
aberrant scores. This assumption is supported by a sug-
gestion that parent-reported number of child behaviour
problems and teacher rated intensity of child behaviour
problems showed improvement on stimulants compared
to placebo treatment for the ECBI. A larger sample size
will provide stronger evidence. A formal series of aggre-
gated n-of-1 trials is currently being conducted.
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